MSR68 Mixture-Cure Modelling of the Overall Survival Outcomes of Patients with Advanced Non-Small Cell Lung Cancer (ANSCLC) Receiving Nivolumab + Ipilimumab in CheckMate-227
- Resource Type
- Abstract
- Source
- In
Value in Health July 2022 25(7) Supplement:S531-S531 - Subject
- Language
- ISSN
- 1098-3015